Akero Therapeutics Inc
1AKRO
Company Profile
Business description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Contact
601 Gateway Boulevard
Suite 350
South San FranciscoCA94080
USAT: +1 650 487-6488
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
67
Stocks News & Analysis
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
A round up of notable stories and reactions as ASX reporting season rolls on.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,181.00 | 36.40 | -0.39% |
| CAC 40 | 7,703.90 | 58.70 | -0.76% |
| DAX 40 | 23,902.21 | 137.71 | -0.57% |
| Dow JONES (US) | 45,544.88 | 92.02 | -0.20% |
| FTSE 100 | 9,187.34 | 29.48 | -0.32% |
| HKSE | 25,528.84 | 451.22 | 1.80% |
| NASDAQ | 21,455.55 | 249.61 | -1.15% |
| Nikkei 225 | 41,906.41 | 812.06 | -1.90% |
| NZX 50 Index | 13,000.64 | 69.91 | 0.54% |
| S&P 500 | 6,460.26 | 41.60 | -0.64% |
| S&P/ASX 200 | 8,911.20 | 37.60 | -0.42% |
| SSE Composite Index | 3,862.65 | 4.72 | 0.12% |